Liver Fibrosis-Pipeline Review, H2 2015

Liver Fibrosis-Pipeline Review, H2 2015


  • Products Id :- GMDHC7289IDB
  • |
  • Pages: 182
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Liver Fibrosis-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Liver Fibrosis-Pipeline Review, H2 2015', provides an overview of the Liver Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Liver Fibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Liver Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Liver Fibrosis Overview 8

Therapeutics Development 9

Pipeline Products for Liver Fibrosis-Overview 9

Pipeline Products for Liver Fibrosis-Comparative Analysis 10

Liver Fibrosis-Therapeutics under Development by Companies 11

Liver Fibrosis-Therapeutics under Investigation by Universities/Institutes 13

Liver Fibrosis-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Liver Fibrosis-Products under Development by Companies 16

Liver Fibrosis-Products under Investigation by Universities/Institutes 19

Liver Fibrosis-Companies Involved in Therapeutics Development 20

Advinus Therapeutics Ltd. 20

AiCuris GmbH & Co. KG 21

Angion Biomedica Corp. 22

Bioneer Corporation 23

BiOrion Technologies B.V. 24

Boehringer Ingelheim GmbH 25

Celgene Corporation 26

Dicerna Pharmaceuticals, Inc. 27

Digna Biotech, S.L. 28

Evotec AG 29

FibroGen, Inc. 30

Galectin Therapeutics, Inc. 31

Genfit SA 32

Gilead Sciences, Inc. 33

GNI Group Ltd. 34

HEC Pharm Co., Ltd. 35

Intercept Pharmaceuticals, Inc. 36

Isarna Therapeutics GmbH 37

KineMed, Inc. 38

LG Life Science LTD. 39

Nitto Denko Corporation 40

Pfizer Inc. 41

Pharmaxis Limited 42

Promedior, Inc. 43

Promethera Biosciences S.A. 44

ProMetic Life Sciences Inc. 45

RuiYi Inc. 46

RXi Pharmaceuticals Corporation 47

SciFluor Life Sciences, LLC 48

TCM Biotech International Corp 49

Vascular Biogenics Ltd. 50

Virobay Inc. 51

XTuit Pharmaceuticals, Inc. 52

Liver Fibrosis-Therapeutics Assessment 53

Assessment by Monotherapy Products 53

Assessment by Target 54

Assessment by Mechanism of Action 57

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

AIC-649-Drug Profile 64

ANG-3281-Drug Profile 65

ANG-4011-Drug Profile 66

Antisense RNAi Oligonucleotide for Liver Fibrosis-Drug Profile 67

Antisense RNAi Oligonucleotide for Liver Fibrosis-Drug Profile 68

BOT-162-Drug Profile 69

CC-539-Drug Profile 70

CC-90001-Drug Profile 71

CIGB-500-Drug Profile 72

CPI-43132-Drug Profile 73

CT-140-Drug Profile 74

DB-036-Drug Profile 75

DCBBO-1202-Drug Profile 76

disitertide-Drug Profile 77

Drugs for Tissue Fibrosis-Drug Profile 80

Drug to Inhibit Galectin-3 for Fibrosis-Drug Profile 81

Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis-Drug Profile 82

elafibranor-Drug Profile 83

F-351-Drug Profile 86

FG-3019-Drug Profile 88

GM-CT-01-Drug Profile 90

GRMD-02-Drug Profile 93

HEC-00000585-Drug Profile 95

HepaStem-Drug Profile 96

INT-767-Drug Profile 98

ISTH-0047-Drug Profile 100

KW-1-Drug Profile 102

LC-280126-Drug Profile 103

melittin-Drug Profile 105

MOR-8457-Drug Profile 106

ND-L02s0201-Drug Profile 107

noscapine-Drug Profile 109

NPLC-0393-Drug Profile 110

P-17-Drug Profile 111

PBI-4050-Drug Profile 113

PRM-151-Drug Profile 114

PXS-4728A-Drug Profile 116

PXS-5033A-Drug Profile 117

Recombinant Enzyme to Replace MMP-9 for Liver Fibrosis and Pulmonary Fibrosis-Drug Profile 118

RXI-209-Drug Profile 119

RYI-018-Drug Profile 120

selonsertib-Drug Profile 121

simtuzumab-Drug Profile 122

Small Molecule for Liver Fibrosis-Drug Profile 124

Small Molecule for Liver Fibrosis-Drug Profile 125

Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis-Drug Profile 126

Small Molecules for Fibrosis-Drug Profile 127

Small Molecules to Antagonize Receptor Tyrosine Kinase for Liver Fibrosis-Drug Profile 128

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis-Drug Profile 129

Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology-Drug Profile 130

TCM-808FB-Drug Profile 131

VB-201-Drug Profile 132

VBY-376-Drug Profile 134

VBY-825-Drug Profile 135

Liver Fibrosis-Recent Pipeline Updates 136

Liver Fibrosis-Dormant Projects 168

Liver Fibrosis-Discontinued Products 169

Liver Fibrosis-Product Development Milestones 170

Featured News & Press Releases 170

Appendix 177

Methodology 177

Coverage 177

Secondary Research 177

Primary Research 177

Expert Panel Validation 177

Contact Us 177

Disclaimer 178

List of Tables

Number of Products under Development for Liver Fibrosis, H2 2015 13

Number of Products under Development for Liver Fibrosis-Comparative Analysis, H2 2015 14

Number of Products under Development by Companies, H2 2015 15

Number of Products under Investigation by Universities/Institutes, H2 2015 17

Comparative Analysis by Clinical Stage Development, H2 2015 18

Comparative Analysis by Early Stage Development, H2 2015 19

Products under Development by Companies, H2 2015 20

Products under Development by Companies, H2 2015 (Contd..1) 21

Products under Development by Companies, H2 2015 (Contd..2) 22

Products under Investigation by Universities/Institutes, H2 2015 23

Liver Fibrosis-Pipeline by Advinus Therapeutics Ltd., H2 2015 24

Liver Fibrosis-Pipeline by AiCuris GmbH & Co. KG, H2 2015 25

Liver Fibrosis-Pipeline by Angion Biomedica Corp., H2 2015 26

Liver Fibrosis-Pipeline by Bioneer Corporation, H2 2015 27

Liver Fibrosis-Pipeline by BiOrion Technologies B.V., H2 2015 28

Liver Fibrosis-Pipeline by Boehringer Ingelheim GmbH, H2 2015 29

Liver Fibrosis-Pipeline by Celgene Corporation, H2 2015 30

Liver Fibrosis-Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015 31

Liver Fibrosis-Pipeline by Digna Biotech, S.L., H2 2015 32

Liver Fibrosis-Pipeline by Evotec AG, H2 2015 33

Liver Fibrosis-Pipeline by FibroGen, Inc., H2 2015 34

Liver Fibrosis-Pipeline by Galectin Therapeutics, Inc., H2 2015 35

Liver Fibrosis-Pipeline by Genfit SA, H2 2015 36

Liver Fibrosis-Pipeline by Gilead Sciences, Inc., H2 2015 37

Liver Fibrosis-Pipeline by GNI Group Ltd., H2 2015 38

Liver Fibrosis-Pipeline by HEC Pharm Co., Ltd., H2 2015 39

Liver Fibrosis-Pipeline by Intercept Pharmaceuticals, Inc., H2 2015 40

Liver Fibrosis-Pipeline by Isarna Therapeutics GmbH, H2 2015 41

Liver Fibrosis-Pipeline by KineMed, Inc., H2 2015 42

Liver Fibrosis-Pipeline by LG Life Science LTD., H2 2015 43

Liver Fibrosis-Pipeline by Nitto Denko Corporation, H2 2015 44

Liver Fibrosis-Pipeline by Pfizer Inc., H2 2015 45

Liver Fibrosis-Pipeline by Pharmaxis Limited, H2 2015 46

Liver Fibrosis-Pipeline by Promedior, Inc., H2 2015 47

Liver Fibrosis-Pipeline by Promethera Biosciences S.A., H2 2015 48

Liver Fibrosis-Pipeline by ProMetic Life Sciences Inc., H2 2015 49

Liver Fibrosis-Pipeline by RuiYi Inc., H2 2015 50

Liver Fibrosis-Pipeline by RXi Pharmaceuticals Corporation, H2 2015 51

Liver Fibrosis-Pipeline by SciFluor Life Sciences, LLC, H2 2015 52

Liver Fibrosis-Pipeline by TCM Biotech International Corp, H2 2015 53

Liver Fibrosis-Pipeline by Vascular Biogenics Ltd., H2 2015 54

Liver Fibrosis-Pipeline by Virobay Inc., H2 2015 55

Liver Fibrosis-Pipeline by XTuit Pharmaceuticals, Inc., H2 2015 56

Assessment by Monotherapy Products, H2 2015 57

Number of Products by Stage and Target, H2 2015 59

Number of Products by Stage and Mechanism of Action, H2 2015 62

Number of Products by Stage and Route of Administration, H2 2015 65

Number of Products by Stage and Molecule Type, H2 2015 67

Liver Fibrosis Therapeutics-Recent Pipeline Updates, H2 2015 140

Liver Fibrosis-Dormant Projects, H2 2015 172

Liver Fibrosis-Discontinued Products, H2 2015 173

List of Figures

Number of Products under Development for Liver Fibrosis, H2 2015 13

Number of Products under Development for Liver Fibrosis-Comparative Analysis, H2 2015 14

Number of Products under Development by Companies, H2 2015 15

Number of Products under Investigation by Universities/Institutes, H2 2015 17

Comparative Analysis by Clinical Stage Development, H2 2015 18

Comparative Analysis by Early Stage Products, H2 2015 19

Assessment by Monotherapy Products, H2 2015 57

Number of Products by Top 10 Targets, H2 2015 58

Number of Products by Stage and Top 10 Targets, H2 2015 58

Number of Products by Top 10 Mechanism of Actions, H2 2015 61

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 61

Number of Products by Top 10 Routes of Administration, H2 2015 64

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 64

Number of Products by Top 10 Molecule Types, H2 2015 66

Number of Products by Stage and Top 10 Molecule Types, H2 2015 66

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advinus Therapeutics Ltd.

AiCuris GmbH & Co. KG

Angion Biomedica Corp.

Bioneer Corporation

BiOrion Technologies B.V.

Boehringer Ingelheim GmbH

Celgene Corporation

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

Evotec AG

FibroGen, Inc.

Galectin Therapeutics, Inc.

Genfit SA

Gilead Sciences, Inc.

GNI Group Ltd.

HEC Pharm Co., Ltd.

Intercept Pharmaceuticals, Inc.

Isarna Therapeutics GmbH

KineMed, Inc.

LG Life Science LTD.

Nitto Denko Corporation

Pfizer Inc.

Pharmaxis Limited

Promedior, Inc.

Promethera Biosciences S.A.

ProMetic Life Sciences Inc.

RuiYi Inc.

RXi Pharmaceuticals Corporation

SciFluor Life Sciences, LLC

TCM Biotech International Corp

Vascular Biogenics Ltd.

Virobay Inc.

XTuit Pharmaceuticals, Inc.

Liver Fibrosis Therapeutic Products under Development, Key Players in Liver Fibrosis Therapeutics, Liver Fibrosis Pipeline Overview, Liver Fibrosis Pipeline, Liver Fibrosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 128320
Site License
USD 4000 INR 256640
Corporate User License
USD 6000 INR 384960

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com